Age at infection affects the long-term outcome of transfusion-associated chronic hepatitis C

Eliseo Minola, Daniele Prati, Fredy Suter, Franco Maggiolo, Flavio Caprioli, Aurelio Sonzogni, Mirella Fraquelli, Silvia Paggi, Dario Conte

Research output: Contribution to journalArticle

108 Citations (Scopus)

Abstract

Before the introduction of hepatitis C virus (HCV) screening for blood donors, the risk of acquiring HCV Infection as a result of a transfusion was about 10%. The aim of this study was to assess the frequency and rate of progression to cirrhosis in patients with transfusion-associated chronic HCV infection and identify possibly negative prognostic factors. Of 2477 consecutive patients with clinical or laboratory evidence of liver disease, 392 (16%) were anti-HCV- and HCV-RNA-positive, had anamnestic evidence of a single and precisely dated transfusion event, and showed no other causes of chronic liver disease; 268 (68%) underwent ultrasound-guided liver biopsy and were enrolled in the study. After a mean interval of 18.4 years, 54 patients (20.1%) had cirrhosis, which multivariate analysis showed to be independently associated with the duration of follow-up, age at infection and at the time of liver biopsy, and serum alanine aminotransferase levels at biopsy. The time necessary to have a 50% probability of developing cirrhosis in patients aged 21-30, 31-40, and more than 40 years was 33, 23, and 16 years, respectively. In comparison with those aged 20 years or less at infection, the risk ratio of developing cirrhosis over a period of 30 years for patients aged 21-30 and at least 31 years at infection was, respectively, 4.51 (95% confidence interval, 1.03-19.76) and 12.29 (95% confidence interval, 3.06-49.40). In patients with transfusion-associated chronic hepatitis C, the risk of cirrhosis is related to age at infection and disease activity. Our findings suggest that an aggressive therapeutic approach should be adopted in patients Infected by HCV at an older age to prevent the progression to end-stage liver disease.

Original languageEnglish
Pages (from-to)4588-4591
Number of pages4
JournalBlood
Volume99
Issue number12
DOIs
Publication statusPublished - Jun 15 2002

Fingerprint

Chronic Hepatitis C
Viruses
Hepacivirus
Liver
Biopsy
Fibrosis
Infection
Virus Diseases
Liver Diseases
Confidence Intervals
End Stage Liver Disease
Alanine Transaminase
Blood Donors
Screening
Blood
Ultrasonics
RNA
Chronic Disease
Multivariate Analysis
Odds Ratio

ASJC Scopus subject areas

  • Hematology

Cite this

Minola, E., Prati, D., Suter, F., Maggiolo, F., Caprioli, F., Sonzogni, A., ... Conte, D. (2002). Age at infection affects the long-term outcome of transfusion-associated chronic hepatitis C. Blood, 99(12), 4588-4591. https://doi.org/10.1182/blood-2001-12-0192

Age at infection affects the long-term outcome of transfusion-associated chronic hepatitis C. / Minola, Eliseo; Prati, Daniele; Suter, Fredy; Maggiolo, Franco; Caprioli, Flavio; Sonzogni, Aurelio; Fraquelli, Mirella; Paggi, Silvia; Conte, Dario.

In: Blood, Vol. 99, No. 12, 15.06.2002, p. 4588-4591.

Research output: Contribution to journalArticle

Minola, E, Prati, D, Suter, F, Maggiolo, F, Caprioli, F, Sonzogni, A, Fraquelli, M, Paggi, S & Conte, D 2002, 'Age at infection affects the long-term outcome of transfusion-associated chronic hepatitis C', Blood, vol. 99, no. 12, pp. 4588-4591. https://doi.org/10.1182/blood-2001-12-0192
Minola, Eliseo ; Prati, Daniele ; Suter, Fredy ; Maggiolo, Franco ; Caprioli, Flavio ; Sonzogni, Aurelio ; Fraquelli, Mirella ; Paggi, Silvia ; Conte, Dario. / Age at infection affects the long-term outcome of transfusion-associated chronic hepatitis C. In: Blood. 2002 ; Vol. 99, No. 12. pp. 4588-4591.
@article{440a69ff8f71485099c613bb939b87b9,
title = "Age at infection affects the long-term outcome of transfusion-associated chronic hepatitis C",
abstract = "Before the introduction of hepatitis C virus (HCV) screening for blood donors, the risk of acquiring HCV Infection as a result of a transfusion was about 10{\%}. The aim of this study was to assess the frequency and rate of progression to cirrhosis in patients with transfusion-associated chronic HCV infection and identify possibly negative prognostic factors. Of 2477 consecutive patients with clinical or laboratory evidence of liver disease, 392 (16{\%}) were anti-HCV- and HCV-RNA-positive, had anamnestic evidence of a single and precisely dated transfusion event, and showed no other causes of chronic liver disease; 268 (68{\%}) underwent ultrasound-guided liver biopsy and were enrolled in the study. After a mean interval of 18.4 years, 54 patients (20.1{\%}) had cirrhosis, which multivariate analysis showed to be independently associated with the duration of follow-up, age at infection and at the time of liver biopsy, and serum alanine aminotransferase levels at biopsy. The time necessary to have a 50{\%} probability of developing cirrhosis in patients aged 21-30, 31-40, and more than 40 years was 33, 23, and 16 years, respectively. In comparison with those aged 20 years or less at infection, the risk ratio of developing cirrhosis over a period of 30 years for patients aged 21-30 and at least 31 years at infection was, respectively, 4.51 (95{\%} confidence interval, 1.03-19.76) and 12.29 (95{\%} confidence interval, 3.06-49.40). In patients with transfusion-associated chronic hepatitis C, the risk of cirrhosis is related to age at infection and disease activity. Our findings suggest that an aggressive therapeutic approach should be adopted in patients Infected by HCV at an older age to prevent the progression to end-stage liver disease.",
author = "Eliseo Minola and Daniele Prati and Fredy Suter and Franco Maggiolo and Flavio Caprioli and Aurelio Sonzogni and Mirella Fraquelli and Silvia Paggi and Dario Conte",
year = "2002",
month = "6",
day = "15",
doi = "10.1182/blood-2001-12-0192",
language = "English",
volume = "99",
pages = "4588--4591",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "12",

}

TY - JOUR

T1 - Age at infection affects the long-term outcome of transfusion-associated chronic hepatitis C

AU - Minola, Eliseo

AU - Prati, Daniele

AU - Suter, Fredy

AU - Maggiolo, Franco

AU - Caprioli, Flavio

AU - Sonzogni, Aurelio

AU - Fraquelli, Mirella

AU - Paggi, Silvia

AU - Conte, Dario

PY - 2002/6/15

Y1 - 2002/6/15

N2 - Before the introduction of hepatitis C virus (HCV) screening for blood donors, the risk of acquiring HCV Infection as a result of a transfusion was about 10%. The aim of this study was to assess the frequency and rate of progression to cirrhosis in patients with transfusion-associated chronic HCV infection and identify possibly negative prognostic factors. Of 2477 consecutive patients with clinical or laboratory evidence of liver disease, 392 (16%) were anti-HCV- and HCV-RNA-positive, had anamnestic evidence of a single and precisely dated transfusion event, and showed no other causes of chronic liver disease; 268 (68%) underwent ultrasound-guided liver biopsy and were enrolled in the study. After a mean interval of 18.4 years, 54 patients (20.1%) had cirrhosis, which multivariate analysis showed to be independently associated with the duration of follow-up, age at infection and at the time of liver biopsy, and serum alanine aminotransferase levels at biopsy. The time necessary to have a 50% probability of developing cirrhosis in patients aged 21-30, 31-40, and more than 40 years was 33, 23, and 16 years, respectively. In comparison with those aged 20 years or less at infection, the risk ratio of developing cirrhosis over a period of 30 years for patients aged 21-30 and at least 31 years at infection was, respectively, 4.51 (95% confidence interval, 1.03-19.76) and 12.29 (95% confidence interval, 3.06-49.40). In patients with transfusion-associated chronic hepatitis C, the risk of cirrhosis is related to age at infection and disease activity. Our findings suggest that an aggressive therapeutic approach should be adopted in patients Infected by HCV at an older age to prevent the progression to end-stage liver disease.

AB - Before the introduction of hepatitis C virus (HCV) screening for blood donors, the risk of acquiring HCV Infection as a result of a transfusion was about 10%. The aim of this study was to assess the frequency and rate of progression to cirrhosis in patients with transfusion-associated chronic HCV infection and identify possibly negative prognostic factors. Of 2477 consecutive patients with clinical or laboratory evidence of liver disease, 392 (16%) were anti-HCV- and HCV-RNA-positive, had anamnestic evidence of a single and precisely dated transfusion event, and showed no other causes of chronic liver disease; 268 (68%) underwent ultrasound-guided liver biopsy and were enrolled in the study. After a mean interval of 18.4 years, 54 patients (20.1%) had cirrhosis, which multivariate analysis showed to be independently associated with the duration of follow-up, age at infection and at the time of liver biopsy, and serum alanine aminotransferase levels at biopsy. The time necessary to have a 50% probability of developing cirrhosis in patients aged 21-30, 31-40, and more than 40 years was 33, 23, and 16 years, respectively. In comparison with those aged 20 years or less at infection, the risk ratio of developing cirrhosis over a period of 30 years for patients aged 21-30 and at least 31 years at infection was, respectively, 4.51 (95% confidence interval, 1.03-19.76) and 12.29 (95% confidence interval, 3.06-49.40). In patients with transfusion-associated chronic hepatitis C, the risk of cirrhosis is related to age at infection and disease activity. Our findings suggest that an aggressive therapeutic approach should be adopted in patients Infected by HCV at an older age to prevent the progression to end-stage liver disease.

UR - http://www.scopus.com/inward/record.url?scp=0037097737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037097737&partnerID=8YFLogxK

U2 - 10.1182/blood-2001-12-0192

DO - 10.1182/blood-2001-12-0192

M3 - Article

VL - 99

SP - 4588

EP - 4591

JO - Blood

JF - Blood

SN - 0006-4971

IS - 12

ER -